FDFaysal Dane

Faysal Dane

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Faysal Dane has a total of 230 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Regional and Gender-Based Distribution of KRAS Mutations in Metastatic Colorectal Cancer Patients in Turkey: An Observational Study

    by Nurullah Ilhan, Faysal Dane, Erdem Goker, Kazım Uygun, Bülent Orhan, Kerem Okutur, İlkay Tuğba Ünek, Abdurrahman Işıkdoğan, Ahmet Bilici, Nurullah Zengin, et al.

    Background and Objectives: KRAS genes are among the most prominent oncogenes that trigger tumor formation in colorectal cancer (CRC) and serve as predictive biomarkers for resistance to anti-EGFR therapies in metastatic colorectal cancer (mCRC) patients. However, the prevalence and mutation spectrum of the KRAS gene family in mCRC patients in Turkey have not been sufficiently analyzed. This study investigates the frequency and distribution of mutations in the KRAS gene family across different regions of Turkey and examines gender-related variations. Materials and Methods: This multicenter observational study included 2458 histologically confirmed mCRC patients collected from 52 centers across Turkey. In a central laboratory, KRAS mutations in codons 12 and 13 were analyzed using polymerase chain reaction (PCR). Statistical analyses were performed using chi-square tests and Monte Carlo simulations, with a significance threshold set at p < 0.05. Results: Depending on the region, KRAS mutations were detected in 45% of patients, ranging from 39.6% to 47.5%. The mutation rate was significantly higher in female patients (48.8%) compared to male patients (42.6%) (p = 0.002). Codon 12 mutations were more frequent than codon 13 mutations. G12D, G12V, and G13D mutations accounted for 80% of all detected mutations. The G12V mutation was prevalent in female patients (p = 0.007). Based on region, mutation diversity was similar, and no statistically significant difference was found (p > 0.05). Conclusions: This large-scale, multicenter study provides the most comprehensive dataset of KRAS mutations in mCRC patients in Turkey. This study revealed regional trends, as well as gender differences. The findings highlight the importance of routine KRAS genotyping in guiding personalized treatment strategies, especially regarding candidate selection for anti-EGFR therapies. Further research is required to elucidate the prognostic and therapeutic implications of specific KRAS mutations.


  • Analysis of survival and prognostic factors in metastatic colorectal cancer patients treated with first line bevacizumab.

    by Nazim Demircan, Faysal Dane, Mehmet Akif Ozturk, Mehmet Besiroglu, Nalan Babacan, Serap Kaya, Ozlem Ercelep, Eda Tanrikulu Simsek, Suleyman Halil, Sinan Koca, et al.

    E15009 Background: Colorectal cancer is a major cause of mortality worldwide. Survival has been improved by usage of bevacizumab. Our study aimed to analyze survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab. Methods: Files of patients were examined retrospectively and 360 patients treated with first-line bevacizumab were included. Data regarding age, gender, family history, location of the primary, histopathology, KRAS status, surgery and chemotherapy were acquired from the files. Overall response rates (ORR) to chemotherapy, progression and exitus dates or dates of last examination were recorded. Median progression-free and overall survival (PFS and OS) were calculated. Survival was analyzed with Kaplan-Meier method. Log-rank test and Cox regression model were used for univariate and multivariate analysis, respectively. Results: 201 (%55,8) of the patients were male and 159 (%44,2) were female. Median age at the time of the diagnosis was 59.5. 260 patients (%72,2) had initially stage IV disease. KRAS was mutant in 125 patients (%34,7). Median PFS was 8.5 months, median OS was 25.3 months and ORR was %51,4. Median PFS was 8.2 and 9.5 months, median OS was 30.4 and 28.1 months, ORR was %62,6 and %58.4 in KRAS wild type and mutant groups, respectively. In patients with left colon cancer median PFS and OS (9.6 and 27.1 months) were superior compared to patients with right colon cancer (7.3 and 19.4 months) (p = 0.005 and 0.016, respectively). Location of the primary, histopathologic grade, primary surgery, metastasectomy and KRAS status affected overall survival significantly (p < 0.05) in univariate analysis. In multivariate analysis, histopathologic grade (p = 0.034) and metastasectomy (p = 0.001) were independent prognostic factors. Conclusions: In our study, response rates and survival of metastatic colorectal cancer patients treated with first-line bevacizumab were similar to previous studies. Left colon cancer patients had superior median PFS and OS compared to right colon cancer patients as shown in recent studies. Histopathologic grade and metastasectomy were independent prognostic factors in correlation with literature.


  • EGFR-targeted treatments in patients with metastatic colorectal cancer: Experience of panitumumab.

    by Mahmut Gumus, Caglayan Geredeli, Mahmut Ucar, Serap Kaya, Hacer Demir, Olcun Umit Unal, Mustafa Degirmenci, Gamze Gokoz Dogu, Nedim Turan, Nilgun Yildirim, et al.

    E15028 Background: Overall survival times have been exceeded three years by the targeted treatments in metastatic colorectal cancer (MCC) . The sequence of these agents and the possible side effects constitute our discussions. We aimed to investigate the efficacy and tolerability of panitumumab use in this study. Methods: In this study 168 MCC patients from 15 different centers that were treated with panitumumab in first or second line settings were evaluated respectively. Progression free survival (PFS) and overall survival(OS) time were calculated in case of the patients treated with targeted treatments in first line setting. Results: The median follow-up time was 12(3-82) months. The median age was 60 (24-86) years and 36 % of the patients were female. Panitumumab as a component of first line treatment was used in 66 % of the patients. Median 6 (1-18) cycles treatment were given to the patients as first line chemotherapy. The median PFS was 11 (SE:2; 95% CI: 7-15) months in patients treated with panitumumab while 12 (SE:1; 95% CI: 10-14) months in patients treated with bevacizumab containing regimens as first line treatment (p:0.836). The median OS was 32 (SE:12; 95% CI: 7-56) months in patients treated with panitumumab containing regimen and the median OS has not been reached in bevacizumab group (p: NS). In univariate analysis, female gender and left-sided colon tumors have favorable PFS (p:0.030 and p:0.023 respectively). No difference between bevacizumab or panitumumab containing regimen in right- sided tumors have observed (p:0.812). But in left-sided tumors, the panitumumab containing regimens have favorable PFS (8 vs 13 months. p:0.023). Grade 2 or higher skin rash was observed in 49% . Diarrhea in 38%, neuropathy in 30%, different hematologic toxicity in 14% and infusion reaction in 2.2% of the patients were detected. The skin rash was associated to panitumumab containing regimen (p:0.000). Other toxicity frequencies were not statistically significant in both groups. Conclusions: Compilation of current life data in MCC treatment will reveal the efficacy and tolerability in our daily practice beyond as data in clinical trials. These data together with more experience will guide the optimization of the treatments.

    • 9 June 2016
      • Vol. 21  (2) , 456-60

    Multicenter experience of adult medulloblastoma: A study of Anatolian Society of Medical Oncology (ASMO).

    by Onur Esbah, Umut Demirci, Faysal Dane, Yusuf Gunaydsin, Nuriye Ozdemir, Ahmet Siyar Ekinci, Hilmi Kodaz, Dogan Yazilitas, Rashad Rzayev, Yildiz Guney, et al.

    Medulloblastoma (MB) is rarely seen in adults. For adjuvant therapy in adults the same therapy protocols used in pediatric cases are used. The present study retrospectively evaluated the data of MB patients who were treated in different Oncology Centers in Turkey. The data of 60 adult patients with MB from 8 Oncology Centers diagnosed between 2005 and 2012 were retrospectively analyzed. The median patient age was 28.8 years (range 16-54). The administered chemotherapy included procarbazine+lomustin+vincristine (group A, N=31) and cyclophosphamide/ifosfamide+vincristine+cisplatin (group B, N=13). Median chemotherapy courses were 4 (range 1-8). Median progression free survival (PFS) was 76 months and median overall survival (OS) has not been reached in both groups. In young female patients and in those who received adjuvant chemotherapy, median PFS and OS were longer but without statistical significance. Mean PFS and OS were 65.9 months and 101.2 months in group A and 113.6 months and 141.6 months in group B, respectively. Improved survival results were obtained in women, in patients aged below 25 years, in those who underwent gross total excision (GTE) and in those who received adjuvant therapy with cyclophosphamide/ifosphamide.

  • The relationship between pretreatment positron emission tomography (PET) results and demographic, histopathologic parameters in patients with locally advanced breast cancer.

    by Mahmut Gumus, Serap Kaya, Hatice Odabas, Aydin Aytekin, Nilgun Yildirim, Teoman Sakalar, Dincer Aydin, Mehmet Bilici, Haci Mehmet Turk, Faysal Dane, et al.

    E23135 Background: Neoadjuvant chemotherapy has been accepted as standart treatment in locally advanced breast cancer recently. 18-FDG-PET/CT is frequently used method for the staging of disease before treatment. We aimed to investigate the role of PET/CT in staging and detection of distant metastasis in addition the relationship of PET/CT with demographic and histopathologic characteristics. Methods: In 6 centers of the different cities of our country, the patients scanned with PET/CT before NAC were evaluated. The SUV of the primary tumor and axilla, age, menopausal status, performance status, clinical stage, tumor localization, hormonal receptor status, presence of Her2 expression, and molecular subtypes of the patients were recorded. ″Mean SUV″ was accepted as mean of the SUVmax of the primary tumor and axilla. Mann-Whitney U ve Kruskall-Wallis H tests were used to investigate the relationship between mean SUV and demographic and histopathologic characteristics. Results: In this study 317 patients were evaluated. Median age was 49(20-82). Of the patients 10.4% was below 35 years, 52% was premenopausal, 89% had ECOG PS:0, 84.5% had stage III disease. In 45.1% of the patients tumor localization was on the right breast. Endocrine sensitivity was 80.1%, Her2 positivity was 42.9% and triple negative molcular subtype was 8.2% of the patients. Mean SUV was found to be significantly higher in patients without hormone sensitivity (ER and PR negative)(p = 0.033). There was a statistically trend between clinical stage and molecular subtype with mean SUV (p = 0.098 and 0.063 respectively). Mean SUV was found to be higher in stage III and triple negative patients. There was no significant relationship between Mean SUV and other parameters(p > 0.05). Conclusions: Taking into consideration of the demographic and histopathological characteristics will increase the success of the treatment in breast cancer patients. Furthermore, PET/CT findings and high level of mean SUV may guide the agressiveness of the tumor.

  • Changes in 18F-FDG-PET/CT tumor metabolism and prediction of pathologic complete response rates after neoadjuvant chemotherapy in hormone-positive breast cancer.

    by Serap Kaya, Bilge Aktas, Eda Tanrikulu Simsek, Mehmet Akif Ozturk, Fuat Dede, Handan Kaya, Umit Mustafa Ugurlu, Zerrin Ozgen, Sinan Koca, Suleyman Halil, et al.

    E12088 Background: Neoadjuvant chemotherapy (NAC) by reducing the tumor size provides higher operability and breast conserving surgery rate in locally advanced breast cancer (LABC) with an advantage to evaluate chemotherapy response. The aim of this study was to assess the predictive value of relative changes in standard uptake values (SUVmax) of 18F-FDG-PET/CT for pathologic complete response (pCR) after NAC in hormone-positive breast cancer. Methods: 90 hormone-positive LABC patients treated in Marmara University Pendik Research and Training Hospital Medical Oncology Clinics, Istanbul, Turkey between 2009 and 2015 was screened. Eligibility criteria were receiving histopathological verification of hormone–positive LABC, completed NAC (4-8 cycles) and evaluated for pCR postoperatively, and PET/CT scan was performed before and after NAC (anthracycline and/or taxanes-based plus trastuzumab if necessary). The relative changes of SUVmax both in primary tumor and axilla were determined and assessed for predicting pCR. Fiftyone patients were eligible for this retrospective analysis. Results: The median age was 46 years (26-76). Only 7 out of 51 patients (13.7%) had pCR and 44 (86.3%) patients had residual tumor. There was no significant difference between patients who had > 50% (n = 40) and < 50% (n = 11) SUVmax changes for predicting pCR rates (15% and 18% respectively) (p = 1.00). Four patients in HER-2 positive (n = 20) and 3 patients in HER-2 negative (n = 31) groups achieved pCR resulting in no association between HER-2 positivity and pCR rates (p = 0.296). Difference in Ki67 levels, tumor localization, menopausal status, grade, lymphovascular and perineural invasion were not found to be associated with pCR. Conclusions: SUVmax changes in later cycles of NAC as commonly practiced in oncology clinics was not found to be predictive for pCR in hormone-positive LABC. However, almost 80% of the patients had > 50% decrease in SUVmax and may still have a chance for more conservative surgery and less postoperative morbidity. As a result, 18F-FDG-PET/CT may still have a role to evaluate the tumor response with a need of larger studies and analysis for cost-effectivity .

  • The factors affecting pathologic complete response after neoadjuvant chemotherapy and the role of 18-FDG-PET/CT in patients with locally advanced breast cancer.

    by Faysal Dane, Serap Kaya, Hatice Odabas, Aydin Aytekin, Nilgun Yildirim, Ezgi Coban, Teoman Sakalar, Dincer Aydin, Mehmet Bilici, Mustafa Benekli, et al.

    E12539 Background: Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) has been shown to provide survival advantages in breast cancer. Here, we investigated the role of 18-FDG-PET/CT and other possible factors in predicting pCR after NAC. Methods: The patients who had 18-FDG-PET/CT before NAC in 6 different centers enrolled in this study. SUV max values of the primary tumor and axilla, age, menapousal status, postoperative histopathological characteristics as hormonal receptor status, presence of Her2 expression, vascular, lymphatic and perineural invasion, grade and molecular subtypes of the tumor of the patients were recorded. Receiver-operating curve (ROC) analysis was done to find out the cut-off SUV value for predicting pCR. The effects of all these factors on pCR were determined by chi-square test. Results: In this study, 317 patients were evaluated. Ten percent of the patients were below 35 years of age, 52% was premenapousal, 89% had ECOG performance status 0, 42.9% had Her2 positive disease. Triple negative subtype was detected in 8.2% of the patients. ORR was 87.1% while pCR was achieved in 29.7% of the patients. The predictive cut-off SUV value of 18-FDG-PET/CT for pCR was found as 7.7 by ROC analysis. The sensitivity and specificity for this value were 57% and 64% respectively (AUC = 0.606; p = 0.0018). There was no significant association between pCR and menapousal status, performance status, perineural invasion or grade (p > 0.05). The pCR was found to be significantly higher in patients with hormone receptor negative tumors, patients with Her2 positive tumors, patients with triple negative tumors , patients without vascular and lymphatic invasive tumors and in patients with mean SUV values over 7.7 (p = 0.009, 0.038, 0.047, 0.000, 0.001 respectively). Conclusions: High levels of mean SUV value 18-FDG-PET/CT and some histopathologic parameters may have a role in predicting pCR after NAC in breast cancer patients, and thus give us the clues about the survival of the patients

  • A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+ gastric or gastro-esophageal junction cancer (TOXAG study).

    by Huseyin Abali, Suayib Yalcin, Huseyin Cem Onal, Faysal Dane, Berna Oksuzoglu, Nuriye Ozdemir, Huseyin Mertsoylu, Mehmet Artac, Celalettin Camci, Bulent Karabulut, et al.

    TPS182 Background: Trastuzumab in combination with chemotherapy has been shown to prolong survival of HER2+ esophago-gastric cancer patients. The primary aim of our study was to evaluate safety and tolerability of trastuzumab (T) in combination with oxaliplatine (O), capecitabine (C) and radiation (R) therapy in the adjuvant setting in curatively resected esophago-gastric cancer patients. Methods: Forty patients with IB or higher stages was planned to be recruited and here we report the interim analyses on 22. We would consider the study positive if at least 64.4% of patients could tolerate the therapy. Eligible patients received T 8 mg/kg intravenously (iv) on Day 1 of cycle 1 and 6 mg/kg iv on day 1 of every following 3-weekly cycle for 1 year as 17 cycles, with O 100 mg/m2 iv on Day 1 of cycles 1-3 and C 850 mg/m2 orally twice daily on days 1-14 of cycles 1-3 and on 5 days per week during chemo-radiotherapy. R was given at a total dose of 45 Gy divided into 25 doses on 5 treatment days per week for 5 weeks starting from the 1st day of cycle 4. Results The median age was 57.5 years (Min-Max: 35-74). Of 22 patients; 15 were male (68.2%), 21 (95.5%) had an ECOG PS score ≤ 1, 21 (95.5%) had D2 lymph node resection. There were 11 serious adverse events. Two patients died on therapy; 1 secondary to pulmonary thrombo-emboli, and the other had to cerebral ischemia (thought to be due to Behçet’s disease), and 7 died of progression. There were 6 dose reductions (1 for T, 2 for O and 3 for C), T was stopped in 1 patient, C was interrupted 8 times (mostly during radiotherapy). Patients who have completed 3 cycles of O, C, T and 4th and 5th cycles of chemo-radiation therapy with C and T were defined as tolerable. Out of 22 patients, 19 (86.4%) were tolerable (Chi Square test: p = 0.0623). Median survival time for interim analysis patients (n = 22) was 22 months (95% CI: 11-23 months). Conclusion T in combination with O, C and chemo-radiation with C and T was tolerable with the tolerability rate of 86.4%, in curatively resected HER2 + esophago-gastric cancer adjuvant treatment. Clinical trial information: NCT01748773.


    • 29 April 2015
      • Vol. 62  (137) , 59-64

    Is perineural invasion (PN) a determinant of disease free survival in early stage colorectal cancer?

    by Mehmet Akif Ozturk, Faysal Dane, Sila Karagoz, Deniz Tural, Fatih Selcukbiricik, Fuat Demirelli, Evin Buyukunal, Mustafa Ozguroglu, Hande Turna, Sibel Erdamar, et al.

    The prognostic importance of perineural invasion (PN) in colorectal cancer (CRC) is unclear. The aim of this study to find out whether the PN was an independent stratification factor of postoperative relapse in curatively resected high-risk stage II & III CRC patients who were treated with adjuvant therapy. Data of patients with high risk stage II & all stage III CRCs treated with adjuvant chemotherapy were retrospectively analyzed. Pathological features of final surgical specimen were noted. Disease-free survival was determined by Kaplan-Meier estimator, with differences determined by multivariate analysis using the Cox multiple hazards model. Results were compared using the log-rank test. PN was found to be positive in 26% in the files of 593 eligible patients. In 21% of the reports PN status was not reported. Presence of PN in the resected primary tumors did not have independent effect on DFS. Further analyses for importance of PN on DFS of colon or rectal cancers did not show any effect. This study had failed to demonstrate any prognostic effect of PN for DFS in surgically resected stage II and III CRC patients who received adjuvant treatments.

    • 5 June 2014
      • Vol. 61  (129) , 259-66

    Analysis of resected gastric cancer in Turkish population.

    by Gokhan Demir, Diclehan Unsal, Nurullah Zengin, Ozlem Er, Faysal Dane, Suayib Yalçin, Turkish Oncology Group

    Gastric cancer is still an important health issue in Eastern Europe and Middle East, including Turkey, although its prevalence is decreasing in the western world. In order to define the profiles of the patients operated with a diagnosis of gastric cancer in Turkey, a multicenter retrospective study was conducted. Six hundred and forty-eight of the 840 patients with complete data in all parameters were included in the analysis. The median follow-up time was 17.16 months (range, 6-143.63 months). Mean age was 57 +/- 11.7 (19-85). There was a recurrent disease in 42% of the tumors located at cardia, corpus or antrum, and 86% of diffuse tumors (p < 0.0001). The ratio of patients with recurrent disease was greater in stage III and IV tumors There were also greater recurrence ratios in patients with node positive (pN1-3) patients than pN0 tumors, and pT3-4 tumors than pT1 or pT2 tumors. Any recurrence was found in 48% of the tumors with lymphovascular invasion, while in 39% without lymphovascular invasion (p = 0.026). A statistically significant difference was found in the recurrence status of patients with positive/dissected node ratio of < 10% and > or = 10% (p < 0.0001). Gastric cancer cases in Turkey are seen at a younger age, and at a higher stage. Proximal gastric cancer is seen much less than the western series. Prognostic significance of lymphovascular invasion in both univariate, and multivariate analyses is noteworthy.